Overview
Urine catecholamine testing for vanillylmandelic acid and homovanillic acid is used to evaluate excess catecholamine production in the body. VMA and HVA are end products of catecholamine metabolism and are excreted in urine after breakdown of epinephrine, norepinephrine, and dopamine.
Measurement of urinary VMA and HVA is an important screening and monitoring tool for catecholamine-secreting tumors, especially in children. These tests help in diagnosis as well as in assessing treatment response and disease progression in neural crest tumors
Symptoms
Symptoms related to increased urinary catecholamines are due to excess hormone release. Common features include persistent or episodic hypertension, excessive sweating, palpitations, and anxiety.
Patients may complain of severe recurrent headaches, flushing, tremors, and unexplained weight loss. In children, symptoms may be subtle and include abdominal mass, bone pain, irritability, or failure to thrive.
Symptoms are often episodic and may worsen during stress, physical exertion, or emotional stimuli.
Causes
Elevated urinary VMA and HVA levels are caused by tumors arising from neural crest cells that secrete catecholamines. The most common causes include neuroblastoma, pheochromocytoma, ganglioneuroblastoma, ganglioneuroma, and other adrenal tumors.
In these conditions, excessive production of catecholamines leads to increased breakdown into VMA and HVA, which are then excreted in urine. Increased levels reflect tumor activity and burden.
Risk Factors
Children are at higher risk for neuroblastoma and related neural crest tumors, making urine catecholamine testing especially important in pediatric populations.
Adults with unexplained hypertension, excessive sweating, or adrenal masses are at increased risk for pheochromocytoma. Genetic predisposition and family history of endocrine tumors also increase risk.
Stress, certain medications, and improper urine collection may influence catecholamine levels and should be considered during interpretation.
Prevention
There is no direct prevention for catecholamine-secreting tumors. Early detection through appropriate testing helps prevent complications related to uncontrolled hormone release.
Proper urine collection, especially 24-hour urine sampling with preservative, ensures accurate measurement. Monitoring VMA and HVA levels during and after treatment helps assess response and detect recurrence early.
Timely diagnosis and management reduce long-term complications such as cardiovascular damage caused by prolonged catecholamine excess.
